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PURPOSE. To develop a tear molecule level-based predictive model based on a panel of tear
cytokines and their correlation with clinical features in ocular chronic graft versus host
disease (cGVHD).
METHODS. Twenty-two ocular cGVHD patients and 21 healthy subjects were evaluated in a
controlled environmental research laboratory (CERLab). Clinical parameters were recorded,
and tears were collected. Levels of 15 molecules (epidermal growth factor [EGF], IL receptor
antagonist [IL-1Ra], IL-1b, IL-2, IL-6, IL-8/CXCL8, IL-10, IL-12p70, IL-17A, interferon inducible
protein [IP]-10/CXCL10, IFN-c, VEGF, TNF-a, eotaxin 1, and regulated on activation normal T
cell expressed and secreted [RANTES]) were measured by multiplex-bead assay and
correlated with clinical parameters. Logistic regression was used to develop a predictive
model. Leave-one-out cross-validation was applied. Classification capacity was evaluated in a
cohort of individuals with dry eye (DE) of other etiologies different from GVHD.
RESULTS. Epidermal growth factor and IP-10/CXCL10 levels were significantly decreased in
ocular cGVHD, positively correlating with tear production and stability and negatively
correlating with symptoms, hyperemia, and vital staining. Interleukin-1Ra, IL-8/CXCL8, and IL-
10 were significantly increased in ocular cGVHD, and the first two correlated positively with
symptoms, hyperemia, and ocular surface integrity while negatively correlating with tear
production and stability. Predictive models were generated, and the best panel was based on
IL-8/CXCL8 and IP-10/CXCL10 tear levels along with age and sex, with an area under the
receiving operating curve of 0.9004, sensitivity of 86.36%, and specificity of 95.24%.
CONCLUSIONS. A predictive model based on tear levels of IL-8/CXCL8 and IP-10/CXCL10
resulted in optimal sensitivity and specificity. These results add further knowledge to the
search for potential biomarkers in this devastating ocular inflammatory disease.
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Graft versus host disease (GVHD) is a major cause ofnonrelapsing mortality and morbidity after allogeneic
hematological stem cell transplantation (HSCT). Hematological
stem cell transplantation has rapidly evolved in recent years,
resulting in an increase in the number of recipients who
become long-term survivors. Thus patient quality of life and the
possibility of late complications have become increasingly
important.1 Graft versus host disease is an immune-mediated
inflammatory disease that causes destruction of host tissues by
immunocompetent cells from the donor.2 There are two forms
of GVHD, acute (aGVHD) and chronic (cGVHD), and differen-
tiation between the two forms is currently based on clinical
manifestations. Typical ocular complications in aGVHD are
pseudomembranous conjunctivitis and acute hemorrhagic
conjunctivitis, which appear in approximately 12% to 17% of
GVHD patients.3,4 However, ophthalmic findings are more
frequent in chronic GVHD. Approximately 30% to 70% of
human leukocyte antigen-matched patients develop cGVHD.3
Ocular manifestations occur in up to 60% to 90% of patients
with cGVHD, primarily affecting structures of the ocular
surface.4
Ocular cGVHD usually mimics typical dry eye (DE); it
frequently severely impairs the patient’s quality of life with
highly disturbing symptoms and may cause severe vision loss
due to corneal involvement.5 According to the National
Institutes of Health (NIH) consensus criteria definition,
‘‘diagnosis of chronic GVHD requires at least 1 diagnostic
manifestation of cGVHD or at least 1 distinctive manifestation
plus a pertinent biopsy, laboratory, or other tests (e.g.,
Schirmer’s test).’’6 However, in 2007 the International Dry
Eye WorkShop recognized the lack of adequately validated and
objective tests to diagnose DE.7 The lack of correlation
between symptoms and signs in DE (also shown among our
own patients)8 greatly complicates DE diagnosis, and is the
main culprit in the frequent failure of clinical trials due to the
scarcity of reliable evaluation end points. For this reason, efforts
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are being made to find objective biomarkers that could be used
as diagnostic, prognostic, and monitoring tools.9 Inflammatory
mediators are being analyzed as potential biomarkers, and to
date, an increasing number of cGVHD candidate biomarkers
are available for further investigation.9 Some research groups
have reported the possibility that levels of certain cytokines in
serum can serve as specific biomarkers of GVHD and thus have
the potential to act as accurate diagnostic and prognostic
tools.10,11 Regarding ocular cGVHD, our group has already
shown that inflammatory gene expression in conjunctival
epithelial cells may act as biomarkers for this disease.12
However, identifying tear biomarkers in ocular cGVHD is even
more desirable, because tears can easily be obtained in a
noninvasive manner, and their close anatomical relationship to
the disease site makes them highly specific for ocular disease.
With the description of changes in tear cytokine levels,
significant progress has been made toward the characterization
of underlying inflammatory mechanisms in the ocular surface
in DE patients.13–15 Despite this progress, little is known about
the specific pathogenesis of ocular cGVHD. Some studies have
already found differences in some tear cytokine levels in
cGVHD patients, particularly one study by Riemens et al.,16
and recently (2015) another one by Jung et al.,17 which
suggested that tear cytokines are useful biomarkers for the
diagnosis of cGVHD.
It is clear, however, that any single biomarker lacks the
sensitivity and specificity needed for most clinical applica-
tions.18 Thus, multivariate predictive modeling techniques
have emerged as useful tools to easily manage not just a single
biomarker but a panel of biomarkers, which increases the
diagnostic and prognostic power. Such models may be
designed to predict a classification variable, for example,
susceptibility to ocular cGVHD, based on known continuous
parameters, that is, cytokine tear levels. Predictive models have
also focused on clinical parameters in an effort to determine
which aspects are most predictive of ocular cGVHD diagno-
sis.19 Additionally, model validation is necessary as it gives
important information about the reliability of the process.
Thus, the purpose of this study was to develop and validate a
prediction model for the diagnosis of ocular cGVHD based on
the levels of a panel of inflammatory mediators in tears and the
correlation of those mediators with the clinical ophthalmic
phenotype.
MATERIALS AND METHODS
Patients and Healthy Controls
This study was approved by the Institute of Applied
OphthalmoBiology (IOBA) institutional review board and the
University of Valladolid Clinical Hospital Ethics Committee and
followed the tenets of the Declaration of Helsinki. All enrolled
patients and subjects were informed of the nature of this study,
and written consent was obtained from each of them.
Ocular cGVHD patients were selected from those referred
to IOBA by the Hematology Department of the University of
Salamanca Clinical Hospital from among new-onset DE
patients, as we excluded patients with previous diagnosis of
DE. To ensure as much as possible that the results would not
be influenced by the effects of topical medications and/or any
other condition, inclusion and exclusion criteria were estab-
lished to ensure that patients were stable. Consequently, the
most severely affected patients were excluded. For the same
reason, patients included in the study were asked to
discontinue their topical therapies for 7 days before the
samples were taken. Only artificial tears and lubricants were
allowed. Thus, inclusion criteria for patients were as follows:
(1) abnormal results of at least three DE diagnostic tests that
included an ocular surface disease index (OSDI) score > 12
points, fluorescein tear breakup time (T-BUT) < 7 seconds,
corneal fluorescein staining and conjunctival Lissamine green
staining > 1 (Oxford scale), and Schirmer test without topical
anesthesia  5 mm in 5 minutes; (2) feasibility of discontinuing
topical anti-inflammatory medications (artificial tears and
lubricants were allowed) for 1 week, as judged by the
attending ophthalmologist (MC); and (3) patients had to be
systemically stable with GVHD under control and no relapse of
the patient’s primary malignancies and no secondary infections
as judged by the referral physician (DC). Exclusion criteria
included any ocular active disease other than DE, contact lens
wear, any ophthalmic surgery in the past 6 months, any topical
medicine other than artificial tears and lubricants, and any
systemic medication that was not continuous or constant in
treatment and dosage for at least 3 months prior to this study.
Healthy volunteers, similar in age and sex to the study cases,
were selected as the control group and were examined to
make certain their ocular status was within normal limits.
Inclusion criteria were the following: (1) absence of ocular
surface-related symptoms (OSDI score  12 points) and (2)
normal limits in at least two of the following four ocular
surface tests: fluorescein T-BUT ‡ 7 seconds, corneal
fluorescein staining and conjunctival Lissamine green staining
(Oxford scale)  grade 1, and Schirmer test without anesthesia
> 5 mm in 5 minutes. Exclusion criteria for this control group
included any present or previous history of ophthalmic or
systemic disease, ocular allergy, any ophthalmic surgery, under
any medication, pregnancy, or current contact lens wear.
Clinical Examination and Sample Collection
All individuals were evaluated after 20-minute exposure in a
controlled environmental chamber (VISIO´N IþD, SL; Valladolid,
Spain) located in the Controlled Environmental Research
Laboratory (CERLab) at IOBA, University of Valladolid, Valla-
dolid, Spain, with the purpose of normalization and standard-
ization of the conditions of clinical evaluation and collection of
samples. The temperature was maintained at 238C and the
relative humidity (RH) at 45%, which corresponds to a
comfortable indoor temperature and the average RH in
Valladolid.20–22
Clinical evaluation was always performed by the same
clinicians (LC, VM), each one always evaluating the same
tests in the following sequence. First, the OSDI question-
naire, which consists of 12 questions, was administered, and
the presence of symptoms over the preceding week was
assessed.23 The OSDI questionnaire was performed for each
eye separately, and the eye with the higher score was
selected as the most symptomatic and used in clinical
evaluation and for tear sampling. A random data table was
used to select the study eye in those cases where both eyes
were equally symptomatic and for control subjects. Second,
tear sample collection was performed before any other tests
to avoid any ocular vital dye interference. As previously
described by our group,15 we used a glass capillary tube
(Drummond Scientific Co., Broomall, PA, USA) to collect a 1-
lL tear sample from the external canthus, avoiding tear reflex
as much as possible. The collected sample was then
deposited into a sterile tube containing 9 lL cold cytokine
assay buffer (Millipore Ibe´rica, Madrid, Spain) and immedi-
ately frozen at 208C and stored at 808C until assayed. Tear
samples were not pooled. Third, conjunctival hyperemia was
evaluated under a slit-lamp and scored on the Nathan-Efron
scale (0–4).24 Fourth, tear stability was evaluated by
measuring T-BUT. Five microliters of 2% sodium fluorescein
was gently applied into the outer third of the inferior fornix
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with a micropipette. The time between the last of three
blinks and the appearance of the first dry spot was measured
three times, and the mean value was recorded. Fifth, ocular
surface integrity was evaluated at the cornea and at the
interpalpebral bulbar conjunctiva by vital staining. Corneal
integrity was evaluated with a slit-lamp mounted with a
cobalt blue filter (Topcon Corp., Tokyo, Japan) and a yellow
Wratten no. 12 filter (Eastman Kodak, Rochester, NY, USA).
The evaluation was done 2 minutes after instillation of 5 lL
2% sodium fluorescein. For the evaluation of conjunctival
integrity, Lissamine green strips (GreenGlo; HUB Pharmaceu-
ticals, LLC, Rancho Cucamonga, CA, USA) were wetted with
25 lL sodium chloride and then gently applied into the
inferior fornix. Corneal and conjunctival staining were
scored using the Oxford scale (score 0–5).25 Sixth, tear
production was assessed by Schirmer test without topical
anesthesia. This test was performed using a Schirmer sterile
strip (TearFlo; HUB Pharmaceuticals, LLC, Rancho Cucamon-
ga, CA, USA) placed in the lateral canthus of the inferior lid
margin. The length of wetting was measured in millimeters
with eyes closed for 5 minutes.
Analysis of Tear Cytokines/Chemokines
The presence and concentration of 15 molecules were
determined in tear samples by a multiplex immunobead-based
array (Milliplex 15x-MPXHCYTO-60 Human Cytokine/Chemo-
kine Panel; Millipore, Watford, UK), using a Luminex IS-100
(Luminex Corporation, Austin, TX, USA). The following
molecules were assayed: epidermal growth factor (EGF),
interleukin (IL) 1 receptor antagonist (IL-1Ra), IL-1b, IL-2, IL-
6, IL-8/CXCL8, IL-10, IL-12p70, IL-17A, interferon inducible
protein (IP)-10/CXCL10, eotaxin 1/CCL11, interferon gamma
(IFN-c), vascular endothelial growth factor (VEGF), tumor
necrosis factor alpha (TNF-a), and regulated on activation,
normal T cell expressed and secreted (RANTES)/CCL5.
Samples were analyzed as previously described,15 following
the manufacturer’s protocol.
Statistical Analysis
Statistical analysis was performed by a licensed statistician (IF)
using the R software (R Foundation for Statistical Computing,
Vienna, Austria). Statistical significance was set at 5%.
Sample size was statistically determined. Statistical power
analysis for logistic regression with continuous predictor and a
balanced design determined that a sample of 19 subjects per
group would give 80% statistical power to detect odds ratio of
2.5 at a significance level of 0.05.
Quantitative data were expressed as means 6 standard
deviations (SD), and qualitative variables were described in
percentages. Median and interquartile range (IQR) were used
to summarize distributions of ordinal variables. Univariate tests
to check differences in the distribution of each variable across
the studied groups were performed. Normality assumption was
checked by the Shapiro-Wilk test. To compare quantitative
characteristics, we used the Student’s t-test for two indepen-
dent samples or the nonparametric alternative, Mann-Whitney
U test, if the normality hypothesis was not valid. To check
homogeneity of variances, the Brown-Forsythe test was used.
When there was significant heterogeneity of variance, Welch’s
t-test was employed. To assess the association between
qualitative variables and group, the v2 test was used or Fisher’s
exact test with small expected frequencies.
To quantify correlations between cytokine levels and
clinical parameters, the Spearman ranked correlation coeffi-
cient (q) was used. Moreover, a bootstrap confidence interval
(CI) for this coefficient was built, using 5000 bootstrap
samples.
Tear Cytokine/Chemokine-Based Predictive Model
Development and Validation
Cytokines were analyzed as log-transformed variables. Cytokine
levels below the limit of detection were imputed using the
robust regression on order statistics (robust ROS) method
introduced by Helsel and Cohn26 and implemented in the
NADA (nondetects and data analysis) R package.27 However,
molecules that were detected in less than 50% of the samples
were not further analyzed.
Logistic regression, adjusted for age and sex, was used to
quantify the association between ocular cGVHD group and
each cytokine separately. Molecules associated with the
outcome at the 10% significance level were identified as
candidate biomarkers. Potential biomarkers were evaluated
simultaneously to fit a multivariate logistic regression model.
The final panel of inflammatory molecules in ocular cGVHD
patients was defined as the optimal subset of potential
biomarkers. The first step was to identify the few most
important candidate biomarkers that help in predicting ocular
cGVHD. An exhaustive search was conducted, building
logistic regression models with every possible combination
of candidate molecules and age and sex as confounding
variables. The optimal model was the one with the minimum
Akaike information criterion value. The variance inflation
factor (VIF) measure was used to check for multicollinearity.
A VIF greater than 5 was considered evidence of multi-
collinearity.
The leave-one-out-cross-validation (LOOCV) procedure was
used to estimate the prediction accuracy of the fitted model,
and receiver operation characteristic (ROC) curve analysis was
used to assess the discriminate ability. The final model was
evaluated according to the area under the ROC curve (AUC). In
addition, sensitivity and specificity were obtained by setting an
optimal threshold using the pROC (display and analyze ROC
curves) R package.28
The Brier score was used as global measure of precision. It
is based upon individual differences between predicted risks in
terms of likelihood and observed final outcomes, and ranges
from 0 for a perfect degree of agreement to 1 for the worst
possible degree of agreement. We used two methods to
evaluate the calibration of the model, measured as the degree
of agreement between the predicted and observed values. With
the calibration in the large (CL) and calibration slope (CS), a
perfectly calibrated model will have a CL value of 0 and a CS of
1. For these methods, the scores are not bounded, so the
model will be badly calibrated if the values depart from the
optimal values. We also used the Hosmer-Lemeshow test,
which is significant for badly calibrated models.
In order to evaluate the external capacity of the fitted model
to properly classify individuals with DE of different etiologies,
an independent dataset of 48 DE patients (14 Sjo¨gren DE and
34 non-Sjo¨gren-associated DE) and 32 healthy controls from
previously published studies by our group was used,20–22
where tear samples were collected in the same standard
conditions described above. The percentage of individuals
successfully classified was estimated.
RESULTS
Clinical Evaluation
A total of 22 ocular cGVHD patients (15 males, 7 females;
55.6 6 11.6 years; range, 34–72 years) and 21 healthy
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volunteers (12 males, 9 females; 53.1 6 12.6 years; range,
30–75 years) were recruited. There were no significant
differences in sex (P ¼ 0.665) or age (P ¼ 0.4873) between
patients and controls. The clinical histories of the ocular
cGVHD patients, including previous diagnosis for HSCT, time
from HSCT and systemic cGVHD diagnosis to ocular cGVHD
diagnosis, and systemic and topical therapies are shown in
Table 1.
Ocular cGVHD patients had significantly more frequent and
intense ocular surface symptoms than controls, as reflected by
the higher OSDI questionnaire scores (Table 2). Ocular surface
examination revealed that patients had moderate conjunctival
hyperemia (grade 0 in 1 patient, grade 1 in 10 patients, grade 2
in 6 patients, grade 3 in 4 patients, and grade 4 in 1 patient),
although scores were significantly higher compared to control
group scores.














1 Hodgkin disease 36 99 Tacrolimus Autologous serum
0.4% preserved
medroxyprogesterone
2 Non-Hodgkin lymphoma 9 45 None Autologous serum
0.05% unpreserved
cyclosporine A
3 Acute lymphoblastic leukemia 24 63 None None
4 Acute myeloid leukemia 12 60 None Autologous serum
0.1% preserved
fluorometholone
5 Acute myeloid leukemia 3 126 Cyclosporine A None
6 Hodgkin disease 18 67 None Unpreserved 0.05%
cyclosporine A
7 Acute lymphoblastic leukemia 12 Unknown None None
8 Non-Hodgkin lymphoma 38 49 Tacrolimus Autologous serum
0.1% preserved
fluorometholone
9 Myelodysplastic syndrome 3 81 Tacrolimus Autologous serum
10 Acute myeloid leukemia 36 Unknown None None
11 Chronic myeloid leukemia 12 Unknown None 0.1% preserved
fluorometholone
12 Chronic myeloid leukemia 2 Unknown None Autologous serum
13 Acute myeloid leukemia 18 21 Rapamycin 0.1% preserved
fluorometholonePrednisone
Imatinib
14 Myelodysplastic syndromes 1 Unknown Rapamycin Autologous serum
15 Chronic lymphoblastic leukemia 15 Unknown Rapamycin 0.1% unpreserved
dexamethasoneTacrolimus
Methylprednisolone
16 Myelodysplastic syndrome 6 26 Prednisone Autologous serum
17 Chronic myeloid leukemia 27 10 Rapamycin Autologous serum









20 Myelodysplastic syndrome 6 Unknown Tacrolimus Autologous serum
1.5% hydrocortisone
ointment
21 Chronic myeloid leukemia 3 Unknown Prednisone 0.03% tacrolimus
ointment
Autologous serum
22 Acute myeloid leukemia 10 7 Methylprednisolone Autologous serum
0.1% unpreserved
dexamethasone
HSTC, hematopoietic stem cell transplantation; systemic therapy had to be stable for the 3 preceding months of the study per inclusion/
exclusion criteria.
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Regarding tear stability and production, ocular cGVHD
patients had significantly lower T-BUT and Schirmer test scores
than controls. Corneal fluorescein staining and conjunctival
Lissamine green staining scores were significantly higher in
ocular cGVHD patients (Table 2).
Tear Cytokine/Chemokine Detection,
Concentration, and Correlation With Clinical Data
For each of the 15 molecules studied, the percentage of
detection in each group and the concentration in each sample
were analyzed (Table 3). Epidermal growth factor and IL-17A
were detected in significantly fewer ocular cGVHD patients
than in healthy controls. For the other 13 molecules, there
were no differences between the percent of patients and
controls expressing them.
Regarding molecule concentrations, EGF and IP-10/CXCL10
tear levels were significantly decreased, whereas IL-1Ra, IL-8/
CXCL8, and IL-10 were significantly increased in ocular cGVHD
patients compared to healthy subjects (Table 3; Fig. 1).
Interleukin-12, IL-6, IL-8/CXCL8, and RANTES levels were
found significantly increased in males compared to females for
both ocular cGVHD patients and control subjects (Fig. 2).
Interleukin-1Ra and IL-8/CXCL8 tear levels positively corre-
lated with OSDI questionnaire score, conjunctival hyperemia,
fluorescein corneal staining, and Lissamine green conjunctival
staining. They were negatively correlated with T-BUT and
Schirmer test scores (Fig. 3). Epidermal growth factor and IP-
10/CXCL10 levels were positively correlated with T-BUT and
Schirmer test scores, and negatively correlated with OSDI,
hyperemia, and fluorescein and Lissamine green staining. Other
molecules had diverse correlations (Fig. 4): RANTES and TNF-a
correlated positively with age; eotaxin correlated positively with
age and OSDI questionnaire score; IFN-c correlated positively
with age and hyperemia; and IL-10 correlated positively with
OSDI questionnaire score, hyperemia, and corneal fluorescein
staining, and negatively with T-BUT.
Multivariate Predictive Modeling
Logistic regression for each of the cytokines, adjusted for age
and sex, was fitted. Table 4 shows the estimated odds ratio
values (with 95%CI) and AUC based on LOOCV procedure.
Elevated levels of EGF and IP-10/CXCL10 were statistically
identified as protective factors, while higher levels of IL-8/
CXCL8 and IL-1Ra were identified as risk factors for ocular
cGVHD development. The elevated level of IL-10 was a
borderline risk factor. Classification ability of EGF, IL-1Ra, IL-
2, IL-8/CXCL8, IP-10/CXCL10, RANTES, TNF-a, and VEGF was
significant, showing AUC values statistically different from 0.5,
which corresponds to random chance. An exhaustive search to
select the best subset of cytokines for the final multivariate
model was performed. The best models by number of
molecules included in them, based on the lower value of the
Akaike information criterion, are shown in Table 5. Model
based on two cytokines, IL-8/CXCL8 and IP-10/CXCL10, along
with age and sex, was identified as the optimal model. The
estimated odds ratio values were 3.37 (95%CI: 1.24–9.17) and
0.23 (95%CI: 0.07–0.82) for IL-8/CXCL8 and IP-10/CXCL10,
respectively.




n ¼ 22 P Value
OSDI questionnaire 4.29 6 5.11 44.58 6 21.76 <0.0001
Conjunctival hyperemia 0 6 0 1.5 6 0.5 <0.0001
T-BUT, s 6.79 6 2.87 2.39 6 2.30 <0.0001
Corneal fluorescein staining 0 6 0 2 6 1 <0.0001
Lissamine green conjunctival staining 0 6 0 2 6 1 <0.0001
Schirmer test without anesthesia, mm 13.60 6 10.25 3.68 6 2.90 <0.0001
Data are presented as mean 6 standard deviation in OSDI, T-BUT, and Schirmer test. Data are presented as median 6 interquartile range in
hyperemia, fluorescein corneal staining, and Lissamine green conjunctival staining. Significant changes (P < 0.05) are denoted in bold.





P ValueHealthy Controls Ocular cGVHD Patients Healthy Controls Ocular cGVHD Patients
EGF 100 77.27 0.0485 2,154.71 6 2,385.56 357.83 6 527.95 <0.0001
Eotaxin 47.62 72.73 0.1703 69.95 6 61.34 83.75 6 60.95 0.1936
IFN-c 47.62 77.27 0.09 28.24 6 26.56 36.86 6 24.31 0.1203
IL-1b 57.14 63.64 0.9018 15.71 6 14.51 84.65 6 299.02 0.3259
IL-1Ra 100 90.91 0.4884 9,384.52 6 10,474.92 33,330.96 6 26,982.06 0.0007
IL-2 71.43 45.45 0.1566 21.84 6 17.79 20.16 6 17.44 0.8093
IL-6 80.95 86.36 0.6981 51.44 6 48.49 119.5 6 117.4 0.1169
IL-8/CXCL8 95.24 100 0.4884 385.18 6 401.72 7,131.18 6 15,956.77 0.0003
IL-10 76.19 86.36 0.4566 28.16 6 20.74 65.7 6 82.99 0.0253
IL-12 p70 66.67 86.36 0.1623 49.12 6 55.4 59.32 6 53.44 0.1331
IL-17A 61.9 22.73 0.0218 20.89 6 17.74 12.16 6 12.42 0.1913
IP-10/CXCL10 100 90.91 0.4884 60,999.05 6 56,159.34 10,511.33 6 20,431.76 <0.0001
RANTES 80.95 86.36 0.6981 121.74 6 108.6 120.55 6 112.58 0.8126
TNF-a 66.67 72.73 0.92 20.2 6 17.19 36.43 6 74.89 0.3203
VEGF 61.9 81.82 0.2648 415.78 6 347.08 578.01 6 528.14 0.4575
Significant differences (P < 0.05) are denoted in bold.
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Internal Validation
To determine the validity of the IL-8/CXCL8- and IP-10/
CXCL10-based model, internal validation by the LOOCV
procedure was developed. The Brier score obtained corre-
sponded to an accurate model (Table 6). Furthermore, the CL
and CS measures, along with the Hosmer-Lemeshow test,
indicated the absence of calibration problems. The model
obtained an AUC of 0.9004, with a sensitivity of 86.36% and a
specificity of 95.24% (Table 6).
Classification of an External Cohort Without
Ocular cGVHD
In order to evaluate the capacity of the fitted model to properly
classify individuals without ocular cGVHD, we tested it in
cytokine tear levels from a cohort of 48 DE patients (14 severe
Sjo¨gren DE and 34 mild/moderate non-Sjo¨gren-associated DE)
and 32 healthy controls from previously published studies from
our group.20–22 Results showed that the IL-8/CXCL8- and IP-10/
CXCL10-based predictive model (sex and age adjusted) had
100% specificity when classifying both controls and mild/
moderate non-Sjo¨gren-associated DE patients; Sjo¨gren-associat-
ed DE patients were correctly classified as negative for ocular
cGVHD in 78.57% of the cases (Table 7).
DISCUSSION
So far, little is known about the etiopathogenesis of ocular
cGVHD, and this limits the emergence of objective and reliable
diagnostic tests. In this study we intended to identify
molecules that are specifically involved in the pathogenic
mechanisms of this disease. To do this, we analyzed tear levels
of a panel of inflammatory molecules in ocular cGVHD
patients, and we then compared them to those in healthy
subjects. Based on this information, we intended to design a
tear biomarker-based predictive model that may facilitate the
diagnosis of this disease. The final panel of inflammatory
molecules included was defined after analysis of the most
important candidate biomarkers, and logistic regression
models were built with every possible combination of
candidate molecules and age and sex as confounding variables.
Evaluation of the enrolled patients revealed that all of them
suffered a moderate DE, as shown by the clinical test scores.
Ocular cGVHD patients had significantly more DE symptoms,
lower Schirmer test scores, and considerably decreased T-BUT
values compared to healthy controls. The ocular surface
integrity of patients’ eyes, as evaluated by fluorescein and
Lissamine green, was significantly altered compared to
controls. However, the damage was not so severe as to prevent
the patients from stopping their anti-inflammatory topical
medications for 1 week as required by the inclusion criteria.
Sampling patients with more severe disease could potentially
have given different results, but then the confounding effects
of topical medication upon inflammatory molecules could not
have been excluded.
Tear cytokine analysis revealed that levels of EGF and IP-10/
CXCL10 were significantly lower in tears of ocular cGVHD
patients. Epidermal growth factor is secreted mainly by the
lacrimal gland and is one of the most important growth factors
present in human tears. Studies from Pflugfelder et al.13 and
Lam et al.14 found lower levels in patients with Sjo¨gren
FIGURE 1. Molecules with significant differences in tear levels between ocular chronic graft versus host disease patients and healthy subjects. EGF
and IP-10/CXCL10 tear levels were significantly decreased, whereas IL-1Ra, IL-8/CXCL8, and IL-10 levels were significantly increased in ocular
cGVHD patients compared to healthy subjects. Diamonds represent the mean values. EGF, epidermal growth factor; GVHD, chronic graft versus
host disease; IL, interleukin; IP, interferon inducible protein.
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syndrome-associated hyposecretory DE compared to healthy
controls. The significant decrease in EGF tear levels found in
our ocular cGVHD patients is in agreement with those studies,
as cGVHD causes an aqueous-deficient Sjo¨gren-like DE.
Additionally, we found that epithelial growth factor receptor
(EGFR) gene expression in conjunctival epithelial cells of
ocular cGVHD patients decreased by 2.6 fold,12 which
confirms the importance of this finding.
We found that IP-10/CXCL10, a chemotactic molecule that
attracts T-lymphocytes, natural killer cells, and monocytes,29
was also decreased in tears of ocular cGVHD patients.
Activated T cells lead to the release of the chemokines CXCL9,
IP-10/CXCL10, and CXCL11 at tissue sites, and these recruit
CXCR3þ T cells, mediating the tissue damage characteristic of
GVHD.30 The importance of the role of IP-10/CXCL10 in
GVHD patients has been established by different authors.
Using a murine model, Duffner et al.31 concluded that the
migration of donor T cells to GVHD target organs depends on
the expression of CXCR3 and contributes significantly to
GVHD damage and overall mortality. Meanwhile, Piper et al.32
found significantly elevated serum levels of IP-10/CXCL10,
suggesting that the specific interaction of this molecule with its
receptor was critical for the recruitment of T cells to the skin
in patients with acute GVHD. Moreover, Westekemper et al.33
demonstrated by polymerase chain reaction that IP-10/CXCL10
was markedly upregulated in conjunctival biopsies of ocular
cGVHD patients compared with healthy controls. The fact that
this chemokine was decreased in our patients could be due to
selection criteria applied, which allowed only patients whose
GVHD was under relatively good control to be included.
On the other hand, we found that the levels of IL-1Ra, IL-8/
CXCL8, and IL-10 were increased in tears of the ocular cGVHD
group. This is consistent with previous reports of tear levels of
these molecules in patients with DE.13–15,34,35 Interleukin-1Ra
is a naturally occurring cytokine receptor antagonist that
serves as a modulator of immune response, regulating the
agonist effects of IL-1 during chronic inflammatory diseases
such as arthritis.36 Moreover, polymorphisms in IL-1 family
genes have been associated with variability in the production
of the respective cytokines and have been implicated in patient
susceptibility to GVHD.37
Interleukin-8/CXCL8 is one of the major mediators of the
inflammatory response, and patients suffering acute GVHD
develop higher levels at times of maximal clinical signs.38 More
importantly, IL-8/CXCL8 is included in two biomarker panels
that predicted death, treatment failure, and risk of developing
GVHD.18,39 In agreement with these results, previous results
from our group have found that IL-8/CXCL8 gene expression
in conjunctival epithelium from ocular cGVHD patients was
almost five times increased compared to healthy controls.12
More studies are warranted to determine the exact role of IL-8/
CXCL8 in ocular cGVHD, as it seems to play an important role
in the pathogenesis.
Finally, IL-10 is an anti-inflammatory cytokine that reduces
activation of T cells. A lack of this cytokine results in increased
allogeneic T-cell responses and strongly aggravates the course
of the disease.40 Several groups have studied the association
between increased IL-10 levels and GVHD, and in spite of its
anti-inflammatory function, they have reported an association
between increased IL-10 levels and GVHD.41,42 Thus, it has
FIGURE 2. Association between sex and molecule tear levels. IL-12p70, IL-6, IL-8/CXCL8, and RANTES/CCL5 were found significantly increased in
males compared to females for both patients and controls together. Diamonds represent the mean values. IL, interleukin; RANTES, regulated on
activation normal T cell expressed and secreted.
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been suggested that because this molecule is a strong
suppressor of T-cell immunity, high levels of IL-10 might lead
to functional immunodeficiency contributing to a poor disease
prognosis.10 These results are reinforced by a 7.7-fold increase
in IL-10 conjunctival gene expression in ocular cGVHD
patients previously reported by our group.12 Increased levels
of IL-10 are also consistent with those present in tears of
patients with Sjo¨gren syndrome-associated DE.35 Our results
are, however, in disagreement with those reported by Riemens
et al.,16 who failed to detect IL-10 in tear levels of ocular
cGVHD patients. Interestingly, in the same study, Riemens et al.
found increased IFN-c and IL-6 tear levels, both of which they
proposed as key molecules for this disease. However, in our
study, tear levels of these molecules in ocular cGVHD patients
were not significantly different from those in controls. An
explanation for these differences could be the different
diagnostic criteria for ocular cGVHD (based on the National
Institutes of Health consensus criteria) used in each study, a
different tear sample collection method (obtained directly from
Schirmer test strips in the study by Riemens et al.16 instead of
by the capillarity collection in ours), and the potential
influence of topical medications used by patients in Riemens’
study.
Increased IL-10 in tears of GVHD patients has also been
recently described by Jung et al.17 In this study, they
investigated levels of IL-2, IL-4, IL-6, IL-10, IL-17A, INF-c, and
TNF-a in tears of patients after HSCT, trying to evaluate
whether they are associated with the presence of systemic
GVHD, regardless of ocular status. They found that IL-2, IL-10,
IL-17A, INF-c, IL-6, and TNF-a were elevated in patients with
cGVHD compared to transplanted patients without cGVHD.
While our results are in agreement regarding increased IL-10 in
tears of cGVHD patients, we did not find significant increase in
IL-2, IL-17A, INF-c, IL-6, or TNF-a. An explanation for the
FIGURE 3. Correlations between IL-1RA, IL-8/CXCL8, IP-10/CXCL10, and EGF tear levels and clinical parameters. Correlations were determined for
the entire study population, both patients and controls together. m, ocular cGVHD patients; *, control group subjects. Values of hyperemia,
corneal fluorescein staining, and conjunctival Lissamine green staining have been jittered to reduce overplotting. Dashed lines represent the 95%
confidence interval. cGVHD, chronic graft versus host disease; EGF, epidermal growth factor; IL, interleukin; IP, interferon inducible protein; q,
Spearman ranked correlation coefficient.
FIGURE 4. Other correlations between tear molecule levels and clinical parameters. Correlations were determined for the entire study population,
both patients and controls together. m, ocular cGVHD patients; *, control group subjects. Values of hyperemia, corneal fluorescein staining, and
conjunctival Lissamine green staining have been jittered to reduce overplotting. Dashed lines represent the 95% confidence interval. cGVHD,
chronic graft versus host disease; EGF, epidermal growth factor; IL, interleukin; IP, interferon inducible protein; q, Spearman ranked correlation
coefficient.
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discrepancies between the results from the Jung study and
ours might be the different sample of patients and controls
analyzed, as the authors compared a cohort of transplanted
patients with and without cGVHD regardless of their ocular
surface status, while we compared patients certainly diagnosed
with ocular cGVHD with healthy individuals. Also sample
collecting methods were different, as they took tears after
buffer washout, whereas we took basal tears by capillarity
collection. Finally, tear molecule analysis and cytokine array
kits were not exactly the same, as they used a cytometric array
with a BD array (Becton, Dickinson and Company, BD
Biosciences), while we used a Milliplex cytokine array with
Luminex technology. All these methodological differences
might be responsible for the differences found between the
two studies.
In the present study EGF, IL-1Ra, IL-8/CXCL8, and IP-10/
CXCL10 show significant individual diagnostic abilities (IL-10 is
borderline), evidenced by their corresponding individual odds
ratio and AUC values. Significant diagnostic abilities of IL-10
and IL-17A were also described by Jung et al.17 However, we
did not find significant results for IL-6 and TNF-a as described
in their study.17
We also correlated cytokine tear levels and clinical tests
results. There were significant correlations for EGF, IL-1Ra, IL-
8/CXCL8, and IP-10/CXCL10 tear levels with clinical parame-
ters. The majority of the correlations that we found were
intuitive, such as that of IL-8/CXCL8 (proinflammatory) tear
levels correlating with all of the clinical markers of disease
severity. Additionally, EGF showed logical negative correlations
with ocular surface damage tests. We found that IP-10/CXCL10
and IL-1Ra, correlated negatively with tests for ocular surface
damage (fluorescein staining and Lissamine green) and
positively with tear production (Schirmer test) or stability (T-
BUT). These results suggest a response by the tissues that
counteracts the damage. These findings are in agreement with
those described in the literature, as several inflammatory
cytokines have been correlated with clinical parameters in
DE.13,35,43 Additionally, our results agree with those found by
Jung et al.17 regarding correlation between IL-10 and OSDI
score, hyperemia, corneal staining, and T-BUT; in contrast, we
did not find significant correlations between IL-2, IL-6, IL-17A,
IFN-c, and TNF-a with clinical parameters as described by
those authors.17 This might be due to the fact that our
correlation studies include a healthy nontransplanted group,
while Jung et al.17 studied only transplanted patients.
The aim of our study was to develop a tear cytokine-based
predictive model for ocular cGVHD patients. Predictive models
are developed to give health care providers objective estimates
of risks of having a particular disease to assist them in the
decision-making process.44 A variety of such approaches have
recently been used in an attempt to diagnose ocular cGVHD,
including clinical parameters-based predictive models, such as
TABLE 4. Estimated Odds Ratio by Logistic Regression Models for Each of the Tear Molecules, Adjusted by Age and Sex
Molecule OR
95% CI for OR
P Value AUC
95% CI for AUC
Lower Upper Lower Upper
EGF 0.3881 0.2302 0.6545 0.0004 0.8333 0.7073 0.9594
Eotaxin 1.3538 0.7494 2.4453 0.3154 0.3961 0.2196 0.5726
IFN-c 1.5635 0.7963 3.0697 0.1942 0.5455 0.3673 0.7236
IL-1b 1.1648 0.8254 1.6439 0.3854 0.6472 0.4792 0.8152
IL-1Ra 1.7720 1.2091 2.5971 0.0034 0.7078 0.5476 0.868
IL-2 0.8687 0.5246 1.4383 0.5842 0.6861 0.5233 0.849
IL-6 1.3057 0.8859 1.9243 0.1777 0.539 0.3596 0.7184
IL-8/CXCL8 1.7878 1.2060 2.6501 0.0038 0.7446 0.5936 0.8956
IL-10 1.6817 0.9967 2.8373 0.0515 0.5649 0.3847 0.7452
IL-12 p70 1.2188 0.8908 1.6676 0.2160 0.4156 0.2313 0.5999
IL-17A 0.6397 0.3834 1.0674 0.0872 0.4892 0.3083 0.6701
IP-10 /CXCL10 0.4501 0.2766 0.7323 0.0013 0.8182 0.69 0.9464
RANTES 0.9491 0.6275 1.4355 0.8044 0.7424 0.5919 0.893
TNF-a 1.1965 0.6958 2.0574 0.5166 0.6905 0.5287 0.8523
VEGF 1.1107 0.7542 1.6358 0.5951 0.71 0.5538 0.8661
EGF and IP-10/CXCL10 were identified as protective factors, while IL-8/CXCL8 and IL-1Ra were identified as risk factors for the development of
disease. Significant results are denoted in bold. Borderline P values (0.05 < P < 0.08) are denoted in italics. AUCs for each of the single molecule
models are shown. OR, odds ratio.
TABLE 5. Better Multivariate Logistic Regression Models of Ocular cGVHD by Size (Number of Variables)
Age Sex EGF IL-10 IL-17A IL-1Ra IL-8/CXCL8 IP-10/CXCL10 AIC
M0 [ [ 64.64
M1 [ [ [ 49.90
M2 [ [ [ [ 26.32
M3 [ [ [ [ [ 26.72
M4 [ [ [ [ [ [ 26.50
M5 [ [ [ [ [ [ [ 28.27
M6 [ [ [ [ [ [ [ [ *
Variables included in the multivariate model are those that showed a P value less than 0.1 individually: EGF, IP-10/CXCL10, IL-17A, IL-8/CXCL8,
and IL-10 IL-1Ra and confounding variables as age and sex. M0, M1, M2, M3, M4, M5, and M6 are models based on 0, 1, 2, 3, 4, 5, and 6 variables,
respectively. The better model by size is that with the lower AIC; thus the M2 model (two cytokine levels IL-8/CXCL8 and IP-10/CXCL10) was the
best. AIC: Akaike information criterion.
* The complete model does not converge; it is not a valid model.
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the National Institutes of Health Eye Score and Schirmer’s test,19
and a multiple conjunctival gene-based predictive model.12
Multiple biomarker–based models, built upon the simulta-
neous use of a group of biomarkers, may improve performance
compared to the use of a single-molecule analysis for diagnosis
issues. Some investigators have attempted to use proteomic
approaches to identify candidate biomarkers in GVHD
practice, with promising results.18,45,46 Regarding ocular
cGVHD, as mentioned above, our group has already proposed
a biomarker-predictive model based on conjunctival epithelial
EGFR, IL-6, IL-9, and NAMPT gene expression that showed
very good sensitivity and specificity.12 Although tear cytokines
have been proposed by Jung et al.17 as cGVHD biomarkers
based on individual AUC and odds ratio values, to our current
knowledge, no multiple biomarker–based predictive models
have been described utilizing tears of ocular cGVHD patients.
Thus, we intended to apply this technology to the accurate
diagnosis of ocular complications of cGVHD; and the
predictive model that resulted, based on the tear levels of IL-
8/CXCL8 and IP-10/CXCL10, showed very good sensitivity
(86.36%) and specificity (95.24%). As expected, discriminant
capacity of this multiple biomarker model was higher than
those models obtained by any single cytokine alone.
Technical resources available at the time of sample
collection and analysis, compared to the previous method
using impression cytology, make these results more valuable.12
Both gene expression and tear cytokine level predictive models
have shown to have good sensitivity and specificity, although
the latter does not reach the results previously obtained
(sensitivity of 100% and specificity of 92.9%).12 A tear-based
model has the advantage that tears are more accessible and that
the handling is easier than with impression cytology, and tears
can be obtained without the need for anesthesia, which would
make it easier to implement in daily clinical practice.47
Moreover, the advent of point-of-care diagnostic tests for
measurement of molecule levels in tears provides a new
opportunity to diagnose and monitor ocular cGVHD patients in
everyday clinics. The current tear cytokine/chemokine model
also provides complementary information about the processes
studied. However, limitation in the amount of tear sample that
can be obtained from these patients (sometimes even 1 lL is
difficult to obtain) could be a downside of this predictive
model compared to the gene based.
We did perform an internal validation of our predictive
model, but it is known that this is not enough to demonstrate
acceptable outcomes of a model on the initial sample only,
being absolutely necessary to confirm that the model predicts
well in a different subset of individuals.44 In order to further
generalize the discriminatory capability of our model we used
an external cohort of patients with Sjo¨gren DE, non-Sjo¨gren
DE, and healthy controls from previous studies of our
group.20–22 Classification results obtained by our two-mole-
cule-based model seem very promising, as it identified most of
these patients as negative for ocular cGVHD. However, the
external validation cannot be considered complete yet, and it
would be worth checking classifier performance using a new
cGVHD sample with and without ocular involvement.
We want to emphasize that although these cytokines and
chemokines are expected to be elevated in other inflammatory
diseases of the ocular surface, and not to be exclusively increased
in tears of ocular cGVHD patients, based on the very good
preliminary classification results, we are convinced that the
changes observed reflect the underlying origin of the DE disease.
There are a number of limitations in the present study. First
of all, obtaining tear fluid from these severe DE patients who
have very little in the way of tears is a challenge. Fortunately,
bead-based arrays utilizing X-MAP technology overcome this
limitation in sample amount. Also, the low number of ocular
cGVHD patients recruited may be a limitation; but while
currently there are relatively few patients who manifest the
disease, the number is increasing. Additionally, the small
number of patients recruited is the result of the inclusion
criteria, which restricted the participation of severe and
uncontrolled cases that were unable to discontinue their
topical medication. Nevertheless, although the sample in this
study was not big, it was large enough to establish levels of
cytokines/chemokines in tears and serve as the basis for
further studies. We are aware that the predictive model has to
be further validated in a bigger cohort of patients with ocular
cGVHD in order to confirm its sensitivity and that the results
obtained so far are totally relevant.
Finally, one could think that systemic anti-inflammatory
therapy used on these patients may influence cytokine levels in
the tear film. We believe that this is possible, but unfortunately,
the severity of the underlying disease made it impossible to


























The Brier score is a measure of accuracy. The calibration in the large, calibration slope and Hosmer-Lemeshow test are calibration measures. The
AUC, sensitivity, and specificity are discrimination measures for the predictive models.
TABLE 7. Classification Performance of the Fitted Model in a Cohort of Sjo¨gren and Non-Sjo¨gren-Associated DE Patients and Healthy Controls
Well Classified, n Wrongly Classified, n
Percentage of Well-Classified Individuals
% 95%CI
Healthy controls 32 0 100 86.66, 100
Mild/moderate non-SS DE 34 0 100 87.36, 100
Severe SS DE 11 3 78.57 48.82, 94.29
Total 77 3 96.25 88.68, 99.03
SS, Sjo¨gren syndrome; DE, Dry eye.
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remove these medications and analyze tear cytokine and
chemokine levels in untreated patients.
In conclusion, this study shows that ocular cGVHD patients
presented different patterns of inflammatory molecules in tears
compared to normal controls and other kinds of DE. This
information adds further knowledge to the understanding of
the molecular mechanisms underlying this disease. Additional-
ly, the predictive model based on IL-8/CXCL8 and IP-10/
CXCL10 tear levels showed good sensitivity and specificity
results. Due to the accessibility of tear film, it may become a
useful tool in daily clinical practice, as biomarkers are now
considered a cornerstone for the diagnosis of several pathol-
ogies. Future directions include evaluation of these biomarkers
with a larger number of samples collected in prospective
studies that will facilitate the successful design of subsequent
clinical trials.
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